MOSCOW, Nov 20 (PRIME) -- The Russian state research center of virology and biotechnology Vector plans to produce 50,000 doses of its EpiVacCorona anti-coronavirus vaccine until the end of 2020, the Federal Service for Consumer Rights Protection and Human Welfare Oversight said in a statement on Friday.
“Production of 50,000 doses of the vaccine is planned until the end of the year,” and Vector has already produced 15,000 doses, the service said.
Mass vaccination of Russians with the EpiVacCorona vaccine is scheduled for 2021, but small batches of the vaccine will be used until the end of 2020, the service said.
EpiVacCorona is Russia’s second anti-coronavirus vaccine. On November 11, the Russian Direct Investment Fund (RDIF) said that an interim analysis of the third stage clinical trials of the Sputnik V anti-coronavirus vaccine showed a 92% efficiency.
The Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products will finish clinical trials of another anti-coronavirus vaccine in mid-December.
End %%md/jst%%
|
|
